1,261 views
The results of some post-hoc analyses of the data on the use of upadacitinib in rheumatoid arthritis were disclosed during the recent American ACR congress, reassuring us about the efficacy and long-term safety of this Jak inhibitor, currently also indicated for the treatment of psoriatic arthritis and spondylitis. We have explored the efficacy aspects of the treatment with Prof. Giandomenico Sebastiani.